Search Results
Recurrent Ovarian Cancer: QUADRA Trial
Ongoing PARP Trials in Recurrent Ovarian Cancer
Niraparib Monotherapy in Late-Line Ovarian Cancer
Dr. Matulonis Discusses Rationale of QUADRA Trial
Strategies for Managing Recurrent Ovarian Cancer
PARP Inhibition’s Role in Recurrent Ovarian Cancer
Case 4: Recurrent Ovarian Cancer, Platinum-Resistant, BRCA WT
Analyzing the Survival Benefits of Niraparib Dose Modification in Ovarian Cancer
Sequencing for Treatment for Recurrent Ovarian Cancer
Results from the ENGOT-OV16/NOVA trial: efficacy and safety of niraparib in ovarian cancer
PARP Inhibitors in Recurrent Ovarian Cancer
Considerations for Managing Recurrent Ovarian Cancer
